Graf Akcie RGLS (Regulus Therapeutics Inc). Diskuze k akciím RGLS. Aktuální informace RGLS.

Základní informace o společnosti Regulus Therapeutics Inc (Akcie RGLS)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 36.34M
Hodnota podniku (EV) N/A
Tržby 10M
EBITDA N/A
Zisk -14.89
Růst v tržbách Q/Q N/A %
Růst v tržbách Y/Y N/A %
P/E (Cena vůči ziskům) 0.00
Forward P/E -0.03
EV/Sales 3.21
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 3.63
P/FCF N/A
Price/Book 1.40
Účetní hodnota na akcii 0.34
Hotovost na akcii 0.41
FCF vůči ceně -33.65 %
Počet zaměstnanců 24
Tržba na zaměstnance 416.667k
Profit margin -157.21 %
Operating margin -145.60 %
Gross margin 100.00 %
EBIT margin -135.94 %
EBITDA margin -316.54 %
EPS - Zisk na akcii N/A
EPS - Kvartální růst -65.22 %
EPS - Očekávaný růst příští rok 100.00 %
Return on assets -38.61 %
Return on equity -60.96 %
ROIC -34.94 %
ROCE -34.37 %
Dluhy/Equity 0.44
Čistý dluh/EBITDA 2.88
Current ratio 4.65
Quick Ratio 4.65
Volatilita 11.95
Beta 1.04
RSI 28.43
Cílová cena analytiků 1
Známka akcie (dle analytiků) N/A
Insider ownership 4.95 %
Institutional ownership 49.70 %
Počet akcií 87.04M
Procento shortovaných akcií 6.81 %
Short ratio 5.93 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 2012
Země United States

Finanční výsledky akcie RGLS

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$6.832$0.072$0.072$1.194$20.759$7.669
Cost Of Goods Sold------
Gross Profit$6.832$0.072$0.072$1.194$20.759$7.669
Research And Development Expenses$12.349$33.975$53.192$64.305$56.387$41.046
SG&A Expenses$11.317$12.86$17.011$18.391$19.13$11.533
Other Operating Income Or Expenses------
Operating Expenses$23.666$46.835$70.203$82.696$75.517$52.579
Operating Income$-16.834$-46.763$-70.131$-81.502$-54.758$-44.91
Total Non-Operating Income/Expense$-1.757$-1.884$-1.971$-0.338$-1.008$-11.769
Pre-Tax Income$-18.591$-48.647$-72.102$-81.84$-55.766$-56.679
Income Taxes$0.001$0.062$-0.197$-0.004$-0.018$0.001
Income After Taxes$-18.592$-48.709$-71.905$-81.836$-55.748$-56.68
Other Income------
Income From Continuous Operations$-18.592$-48.709$-71.905$-81.836$-55.748$-56.68
Income From Discontinued Operations------
Net Income$-18.592$-48.709$-71.905$-81.836$-55.748$-56.68
EBITDA$-15.903$-44.353$-67.258$-78.56$-51.695$-41.823
EBIT$-16.834$-46.763$-70.131$-81.502$-54.758$-44.91
Basic Shares Outstanding1796444
Shares Outstanding1796444
Basic EPS$-1.08$-5.59$-11.47$-18.59$-12.97$-15.49
EPS - Earnings Per Share$-1.08$-5.59$-11.47$-18.59$-12.97$-15.49
# 2020 2019 2018 2017 2016 2015
Current Ratio1.87090.72412.04716.335510.62844.6872
Long-term Debt / Capital---0.261--
Debt/Equity Ratio0.731-2.83140.56390.3531-0.1772
Gross Margin100100100100100100
Operating Margin-246.3993-64948.61-97404.17-6825.963-263.7795-585.6044
EBIT Margin-246.3993-64948.61-97404.17-6825.963-263.7795-585.6044
EBITDA Margin-232.7722-61601.39-93413.9-6579.564-249.0245-545.3514
Pre-Tax Profit Margin-272.1165-67565.27-100141.7-6854.271-268.6353-739.0663
Net Profit Margin-272.1311-67651.39-99868.06-6853.936-268.5486-739.0794
Asset Turnover0.16240.00260.00090.01190.14710.0447
Inventory Turnover Ratio------
Receiveable Turnover5.98772.76920.1930.72062.071627.9891
Days Sales In Receivables60.958131.80561890.903506.5368176.196613.0408
ROE - Return On Equity-92.909832.063-204.1827-145.9403-44.9298-42.9348
Return On Tangible Equity-94.1415766.5882-208.7773-148.6306-45.3247-43.3121
ROA - Return On Assets-44.1815-174.4154-92.4122-81.2986-39.5143-33.0534
ROI - Return On Investment-92.8903832.0635-204.1828-107.8535-44.9298-42.9348
Book Value Per Share0.9522-0.66394.065612.719328.28132.3792
Operating Cash Flow Per Share3.81474.41063.5482-1.2795-0.8846-1.9193
Free Cash Flow Per Share3.82284.45643.7073-1.1686-0.8909-1.9817